Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 145.5 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control.